How do you get semaglutide in the US?

There are four routes. Branded semaglutide (Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management, now available as both an injection and a once-daily pill) is FDA approved and available by prescription. Telehealth platforms can write that same prescription without an in-person visit. A compounding-pharmacy channel existed during the national shortage but narrowed sharply after the FDA's February 2025 order resolved it. Research-grade semaglutide is also available through the research-compound market for laboratory and pre-clinical study, sourced independent of a pharmacy.

Is semaglutide legal to buy?

Branded semaglutide is a legal prescription medication when dispensed through a licensed pharmacy against a valid prescription, whether that prescription comes from an in-person doctor or a telehealth platform. Research-grade semaglutide is sold for research use only, a real regulatory category describing laboratory-use material, not a workaround for personal use. This guide describes how each market works; it is not medical advice and does not instruct anyone to self-administer.

Can I still get semaglutide from a compounding pharmacy?

Mostly no. The FDA determined the semaglutide shortage was resolved on February 21, 2025, which removed the shortage-based legal basis compounders had relied on. State-licensed 503A pharmacies had until April 22, 2025 and outsourcing facilities (503B) until May 22, 2025 to stop compounding copies, aside from narrow patient-specific exceptions.

Is semaglutide fda approved?

Yes. The semaglutide molecule is FDA approved under three brand names, Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. Wegovy is approved as both a weekly injection and, since December 2025, a once-daily tablet.

Is semaglutide available as a pill?

Yes, two ways. Rybelsus, an oral tablet in 3, 7, and 14 mg strengths, has been FDA approved for type 2 diabetes since 2019. A separate oral tablet, the Wegovy pill, at 1.5, 4, 9, and 25 mg strengths, was FDA approved in December 2025 for chronic weight management after the OASIS 4 trial reported 16.6% mean weight loss with adherence.

What does research use only mean for semaglutide?

It means the material is supplied for laboratory and in-vitro study and is explicitly not intended, tested, or approved for human use in that form. It is a description of the product and its regulation, not a legal loophole for personal use.

How do I know a research-grade semaglutide source is legitimate?

Require a batch-matched certificate of analysis tied to a specific lot (identity by mass spectrometry, purity by HPLC as a measured number, and a characterized impurity profile), ideally verified by an independent third-party lab rather than only the manufacturer's own testing.

How to Get Semaglutide in the US: A 2026 Access Guide

Quick answer

Semaglutide is FDA approved under three brand names, Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management, so a genuine prescription route exists in a way it does not for an investigational compound. ^[2]
The FDA's February 21, 2025 declaratory order resolved the national semaglutide shortage, which narrowed the compounding-pharmacy channel that many people had used to avoid list price. ^[1]
A once-daily Wegovy tablet, FDA approved in December 2025, joined the existing Rybelsus tablet and the weekly injection, so "semaglutide pills" now describes two distinct approved products, not a workaround. ^[6]
With compounding largely closed, the three lanes left in 2026 are the branded prescription route (in person or via telehealth), and the research-compound market, where sourcing quality, not a pharmacy gatekeeper, is what separates a legitimate supplier from a risky one.

Semaglutide is a different animal than most of the compounds discussed on this site, because it already cleared the FDA, and cleared it three separate times, under three separate brand names. That single fact splits its access story into four lanes, and conflating them is where most confusion about how to get semaglutide starts. This guide separates the four, explains what changed in the compounding channel, walks through the telehealth lane that a large share of buyers now use by default, and then focuses in depth on the lane that has no pharmacy gatekeeper at all, the research-compound market.

It is written for research and educational purposes. It describes how each market works and does not instruct anyone to self-administer. For the full clinical picture of what semaglutide is and what its trials showed, see the complete semaglutide guide.

The four ways to get semaglutide in 2026

Semaglutide access routes compared

Route	What it is	Prescription required	Status in 2026
Branded prescription (Ozempic, Wegovy, Rybelsus)	FDA-approved semaglutide manufactured by Novo Nordisk	Yes	Available; list price above $1,000 a month without a savings program
Telehealth prescription	A licensed clinician prescribes the same branded product through an online visit	Yes	Widely used; often paired with manufacturer cash-pay pricing
Compounding pharmacy	Non-branded copies made under a shortage-based exception	Yes	Mostly closed since the FDA's February 2025 order resolved the shortage ^[1]
Research-compound market	Peptide supplied for laboratory and pre-clinical study	No	The route this guide covers in depth

The table is the whole story in outline. What follows fills in why each row looks the way it does, and, for the row without a pharmacy gatekeeper, what actually separates a trustworthy source from a risky one.

The prescription route: Ozempic, Wegovy, and Rybelsus

Semaglutide's single-receptor GLP-1 mechanism was studied across the STEP program for weight management and the SUSTAIN program for type 2 diabetes, and it is the molecule with the longest approved track record of any compound on this site. In the pivotal STEP 1 obesity trial, the 2.4 mg dose produced 14.9% mean body-weight loss at 68 weeks. ^[2] That evidence base is why a doctor can prescribe it and a pharmacy can dispense it, under three different brand names built on the same molecule.

The three approved brands

Brand	Form	Indication	Dose studied
Ozempic	Weekly injection	Type 2 diabetes	Up to 2.0 mg weekly
Wegovy	Weekly injection	Chronic weight management	2.4 mg weekly (STEP 1) ^[2]
Wegovy pill	Once-daily tablet	Chronic weight management	25 mg daily (OASIS 4) ^[6]
Rybelsus	Once-daily tablet	Type 2 diabetes	7 or 14 mg daily

The newest entry in that table is the Wegovy tablet, a once-daily 25 mg pill the FDA approved in December 2025 after the OASIS 4 trial reported 16.6% mean weight loss among participants who adhered to treatment, with roughly one in three reaching 20% or more. ^[6] That is a materially different product from Rybelsus, which has been approved for type 2 diabetes since 2019 at lower 3, 7, and 14 mg doses and was not studied for weight management at that dose range. The two tablets are easy to confuse because both are oral semaglutide from the same manufacturer, and the confusion shows up constantly in searches for semaglutide pills and semaglutide tablets price. "Semaglutide pills" is no longer a single search with a single answer: the two tablets carry different indications, different studied doses, and both require the same absorption workaround (taken fasted, with a small amount of water, and no food for 30 minutes afterward) because oral semaglutide needs an absorption enhancer to survive the stomach long enough to be absorbed at all. ^[3]

The friction in this lane is not legality, it is cost and access. List price without insurance commonly runs above $1,000 a month for the injection and higher still for Wegovy, though Novo Nordisk's direct cash-pay program has pushed the price most people actually pay well below that figure for eligible patients, a detail covered in the cost section below. Insurance coverage depends heavily on the specific plan and the indication: diabetes coverage for Ozempic and Rybelsus tends to be broader than obesity coverage for Wegovy, since many insurers still treat obesity medications as a separate, more restricted benefit category.

Telehealth: the fastest-growing way to get a prescription

A large and growing share of "how to get semaglutide online" and "semaglutide near me" searches are answered by telehealth, not a traditional in-person clinic visit. Telehealth platforms connect a patient to a licensed prescriber over a video or asynchronous visit, and if the clinician determines the prescription is appropriate, it is sent to a pharmacy exactly like any other prescription. This is still the branded prescription lane described above; telehealth changes how the visit happens, not what is dispensed or under what legal basis it is dispensed. Several national platforms, along with pharmacy-adjacent programs run through GoodRx and similar services, now prescribe Ozempic, Wegovy, or Rybelsus this way, often with direct enrollment in Novo Nordisk's cash-pay savings pricing during the same visit.

A clinician still has to determine the prescription is appropriate for that patient, and a telehealth visit does not change the underlying regulatory requirement for a valid prescription. A platform offering semaglutide with no clinician evaluation at all is not a faster telehealth lane, it is outside the prescription system entirely, a meaningfully different, and legally different, thing from what is described here.

What happened to compounded semaglutide

For much of 2022 through early 2025, semaglutide appeared on the FDA's drug shortage list, first for Wegovy in March 2022 and then for Ozempic that August, and that shortage created a legal basis for state-licensed 503A pharmacies and 503B outsourcing facilities to compound non-branded versions, commonly priced at a few hundred dollars a month, a fraction of branded list price. That became a major access route for people priced out of Ozempic or Wegovy.

That changed on February 21, 2025, when the FDA issued a declaratory order determining the semaglutide shortage was resolved across all presentations of the drug. ^[1] The FDA subsequently set an enforcement-discretion window: 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop producing, distributing, and dispensing semaglutide copies, aside from narrow exceptions tied to documented, patient-specific clinical need. An outsourcing-facility trade group sued the FDA over the determination within days, a legal challenge that mirrors the one filed after the agency's earlier tirzepatide shortage resolution. ^[1]

Practically, that means the compounding lane that many semaglutide compound and semaglutide compounding pharmacy searches are still pointed at has narrowed to a fraction of its former footprint. A pharmacy still openly compounding semaglutide at scale in 2026, outside a documented patient-specific exception, is operating outside the position the FDA has staked out, which is itself a red flag worth knowing about before you engage with one.

The research-compound market: what research use only means

With the compounding lane mostly closed and the prescription lane gated by a clinician's evaluation, the market that has no gatekeeper at all is the research-compound market: semaglutide peptide supplied for research use only, intended for laboratory and pre-clinical study, not for human administration. This is a real regulatory category, not a euphemism. It describes what the product is and how it is labeled and sold, and it is worth being precise about because the phrase is widely misread as a wink-and-nod workaround. It is not that. It is an accurate description of the product's intended use.

Because there is no pharmacy standing between a manufacturer and the buyer, no one is checking each batch on the buyer's behalf. That puts the entire burden of quality verification on the buyer's ability to evaluate a supplier, which is the skill this guide is really about, and it is exactly the same discipline described in what to look for when buying semaglutide.

How to evaluate a research-compound source: the checklist

What a trustworthy research source provides

Requirement	What good looks like
Certificate of analysis	Tied to a specific lot number, not a generic catalog spec sheet
Identity	Confirmed by mass spectrometry
Purity	Measured by HPLC, reported as a number, not a claim
Impurity profile	The non-target fraction is characterized, not unknown
Independent testing	Verified by a third-party lab, not only the manufacturer's own
Transparency	The supplier volunteers this documentation rather than dodging it

The single most important item is the batch-matched COA verified by an independent lab. A manufacturer's own certificate is a starting point, not proof, since self-reported figures cannot be audited on their own. A supplier who sends a sample out for independent re-testing and shows you the result is demonstrating the one thing you cannot verify yourself from a listing page.

The two measurements that matter most on that document are identity, confirmed by mass spectrometry, and purity with a characterized impurity profile, measured by HPLC. Purity determination by chromatography is a standardized method. ^[4] The reason the impurity fraction needs to be identified, not just quantified, is the whole basis of impurity-qualification guidance: an unknown 1% carries a different risk than a known one. ^[5]

Red flags to walk away from

No lot-specific COA: a generic spec sheet or a purity claim with no document behind it.
A purity number with no impurity profile. 99% pure means little if no one can say what the other 1% is.
Only the manufacturer's own testing, with no independent verification offered.
A price far below every other listing. Independent testing across lots costs money, and a rock-bottom price often means that step was skipped.
A pharmacy or storefront still marketing compounded semaglutide at scale in 2026 with no documented patient-specific exception, given where the FDA's order left that channel. ^[1]
A source claiming a semaglutide product is a generic version of Ozempic or Wegovy. No FDA-approved small-molecule generic exists yet in the US; the core compound patents run into the early 2030s, so anything marketed as a generic pharmaceutical is either compounded material operating outside the narrowed exceptions, or a mislabeled research compound.
Evasiveness. A source reluctant to produce documentation is telling you something.

Questions to ask a supplier before ordering

A short, direct list separates transparent suppliers from evasive ones. A legitimate source answers all of these without friction:

Can I see the COA for the specific lot I would receive, not a representative or generic one?
Was identity confirmed by mass spectrometry and purity by HPLC?
Is the impurity profile characterized, and what is in it?
Was this verified by an independent lab, or only your own?
Do you test every lot, or only occasionally?

The answers matter less than the willingness to give them. A supplier who treats these as reasonable questions is showing you their process; one who deflects is showing you something too.

What you actually receive

Research-grade semaglutide is supplied as a lyophilized, freeze-dried powder, since dry peptide is far more stable than peptide already in solution. It has to be reconstituted with bacteriostatic water before any laboratory use: added gently, swirled rather than shaken, and stored refrigerated with the date labeled. The full procedure is in how to reconstitute peptides with bacteriostatic water. The point for a buyer is straightforward: a well-sourced vial only stays well-characterized if it is handled correctly once it arrives, so plan for the supplies and the technique, not just the compound itself.

Cost across the four lanes

What each lane typically costs

Route	Typical monthly cost	What drives the price
Branded prescription (list price)	Above $1,000 without a savings program	Manufacturer list pricing before any discount is applied
Branded prescription (manufacturer cash-pay)	Roughly $149 to $499 depending on product and dose	Novo Nordisk's direct self-pay program, introduced and repeatedly lowered through 2025 and 2026
Branded prescription (insured)	Ranges widely, sometimes near copay-only	Plan design; diabetes coverage for Ozempic and Rybelsus is typically broader than obesity coverage for Wegovy
Compounding pharmacy (where it still legally applies)	Was commonly a few hundred dollars during the shortage	Narrower compounding now applies mainly to documented, patient-specific exceptions ^[1]
Research-compound market	Varies by vendor, purity, and independent testing depth	Rigorous third-party testing costs more; the cheapest listing usually means that cost was cut

The manufacturer cash-pay row is the biggest change in this market in the past two years. Novo Nordisk has repeatedly cut its direct self-pay prices for both the injection and the tablets, pulling a meaningful share of buyers who would once have looked at compounding or research-market pricing back into the branded lane, at least at the lower starting doses. The pattern worth internalizing, especially for the cheap semaglutide and semaglutide without insurance searches, is that the gap between branded and alternative lanes narrowed considerably in 2025 and 2026, even as list price stayed high. For the research-compound lane specifically, the same rule holds as in every other lane: the gap between a rigorously verified product and a bargain one is largely the cost of the verification itself, since paying for independent testing is paying to actually know what is in the vial.

I started where most people probably do now, comparing Wegovy's cash-pay price against what I remembered compounding pharmacies charging a couple of years earlier, then tried a telehealth visit that was genuinely fast but still ended near the same list price until the manufacturer's savings program applied. By the time I actually called around to local compounding pharmacies, most had either closed the semaglutide line entirely or added a disclaimer about patient-specific exceptions I didn't qualify for. It took some reading to realize that was the FDA's shortage order working as intended, not a coincidence, and once I ran the numbers with cash-pay pricing stacked in, the branded tablet was closer to research-compound territory than I expected, at least at the starting dose.

Where I landed was the research-compound market, mostly because I wanted a wider range of doses to study than the tablet strengths allow. Sourcing became the whole job at that point. I stopped comparing prices first and started asking for the lot-specific COA first, mass spec for identity, HPLC for purity, an independent lab, not just the manufacturer's own numbers. Any listing that couldn't produce all four got crossed off before I even looked at what it cost.

— Owen Whitfield, Raleigh, NC

Is it legal to buy semaglutide

Branded semaglutide is a legal prescription medication, full stop, when it is dispensed by a licensed pharmacy against a valid prescription, whether that prescription came from an in-person visit or a telehealth platform. Compounded semaglutide is legal only within the narrowed exceptions that remain after the shortage was declared resolved. ^[1] Research-grade semaglutide is sold under the research use only category described above: real, regulated, and explicitly not sold or labeled for human administration. This guide describes how each of those markets works. It is not medical advice, and it does not advise anyone to self-administer a research compound.

Frequently asked questions

How do you get semaglutide in the US?: There are four routes. Branded semaglutide (Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management, now available as both an injection and a once-daily pill) is FDA approved and available by prescription. Telehealth platforms can write that same prescription without an in-person visit. A compounding-pharmacy channel existed during the national shortage but narrowed sharply after the FDA's February 2025 order resolved it. Research-grade semaglutide is also available through the research-compound market for laboratory and pre-clinical study, sourced independent of a pharmacy.
Is semaglutide legal to buy?: Branded semaglutide is a legal prescription medication when dispensed through a licensed pharmacy against a valid prescription, whether that prescription comes from an in-person doctor or a telehealth platform. Research-grade semaglutide is sold for research use only, a real regulatory category describing laboratory-use material, not a workaround for personal use. This guide describes how each market works; it is not medical advice and does not instruct anyone to self-administer.
Can I still get semaglutide from a compounding pharmacy?: Mostly no. The FDA determined the semaglutide shortage was resolved on February 21, 2025, which removed the shortage-based legal basis compounders had relied on. State-licensed 503A pharmacies had until April 22, 2025 and outsourcing facilities (503B) until May 22, 2025 to stop compounding copies, aside from narrow patient-specific exceptions.
Is semaglutide fda approved?: Yes. The semaglutide molecule is FDA approved under three brand names, Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. Wegovy is approved as both a weekly injection and, since December 2025, a once-daily tablet.
Is semaglutide available as a pill?: Yes, two ways. Rybelsus, an oral tablet in 3, 7, and 14 mg strengths, has been FDA approved for type 2 diabetes since 2019. A separate oral tablet, the Wegovy pill, at 1.5, 4, 9, and 25 mg strengths, was FDA approved in December 2025 for chronic weight management after the OASIS 4 trial reported 16.6% mean weight loss with adherence.
What does research use only mean for semaglutide?: It means the material is supplied for laboratory and in-vitro study and is explicitly not intended, tested, or approved for human use in that form. It is a description of the product and its regulation, not a legal loophole for personal use.
How do I know a research-grade semaglutide source is legitimate?: Require a batch-matched certificate of analysis tied to a specific lot (identity by mass spectrometry, purity by HPLC as a measured number, and a characterized impurity profile), ideally verified by an independent third-party lab rather than only the manufacturer's own testing.

Glossary

Ozempic: The FDA-approved brand name for injectable semaglutide indicated for type 2 diabetes, dosed up to 2.0 mg weekly.
Wegovy: The FDA-approved brand name for semaglutide indicated for chronic weight management, available as a 2.4 mg weekly injection or, since December 2025, a 25 mg once-daily tablet.
Rybelsus: The FDA-approved oral semaglutide tablet, in 3, 7, and 14 mg strengths, indicated for type 2 diabetes.
503A pharmacy: A state-licensed compounding pharmacy that can prepare patient-specific medications under narrower rules than an outsourcing facility.
503B outsourcing facility: A compounding facility registered with the FDA that can produce larger batches, subject to its own set of federal requirements.
Drug shortage declaratory order: A formal FDA determination of whether a drug's shortage status is ongoing or resolved, which governs what compounders may legally produce.
Research use only (RUO): Material supplied for laboratory or in-vitro study, explicitly not intended, tested, or approved for human use.
Certificate of analysis (COA): A lab document reporting the measured identity and purity of a specific production lot.
HPLC: High-performance liquid chromatography, which separates and quantifies a compound and its impurities to measure purity.

References

U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (February 21, 2025).
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
Knop FK, et al. Oral semaglutide 50 mg taken once daily, for the treatment of overweight or obesity (OASIS 1). The Lancet. 2023;402(10403):705-719.
United States Pharmacopeia (USP). General Chapter <621> Chromatography: HPLC purity determination methods.
ICH Q3A(R2). Impurities in New Drug Substances: guideline on characterizing and qualifying impurities.
Novo Nordisk. FDA approves the Wegovy pill (oral semaglutide 25 mg) for chronic weight management, based on OASIS 4 trial results. Company announcement, December 22, 2025.

For research and educational purposes only. Not medical advice. This guide describes how the branded prescription market (including telehealth), the compounding-pharmacy market, and the research-compound market work, and how to evaluate a research-compound supplier; it does not instruct anyone to self-administer. Research-grade semaglutide is sold for laboratory and pre-clinical study and is not approved for human use in that form.